Zhejiang Hisoar Pharmaceutical Co., Ltd.

Zhejiang Hisoar Pharmaceutical Co., Ltd., is a public listed company held by DanKong Group, mainly manufacturing APIs, formulations, fine chemicals, dyestuffs and dyetuff Intermediates. Hisoar Pharma with its headquarter located in Taizhou, Zhejiang Province, has nearly 3000 employees and 30 subsidiaries in Zhejiang, Shanghai, Jiangsu, Hubei, Hainan, Hong Kong SAR, Singapore and Germany. Hisoar has 2 main R&D center in both Shanghai and Taizhou, with around 200 R&D personnel. Hisoar achieves honours of "National Enterprise Technology Center", "National Postdoctoral Workstation", "Zhejiang Academician Expert Workstation". It is one of the top 100 innovative enterprises in the national pharmaceutical industry and a key high-tech enterprise in the National Torch Plan. Nearly 70% pharmaceutical products of Hisoar are exported to Europe, United States and other overseas markets. Penem series products have obtained numbers of national invention patents, and Hisoar is one of the largest manufacturers in the world; Clindamycin series maintain a leading market share in domestic output and export volume; Flofenicol maintain a leading market share in regulatory market share. The manufacture plants have been approved by U.S. FDA, EU EDQM, Japanese PMDA, German BJV, Brazilian ANVISA, Chinese NMPA and MOA for many times, with nearly 60 international and domestic registered approvals. Hisoar has established strategic partnerships with Pfizer, Boehringer Ingelheim, and has established long term business relationship with Novartis, Sanofi, GSK, BASF, Sumitomo, Dystar, Archroma and other world-renowned pharmaceutical and chemical companies over the years.